{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:31:12Z","timestamp":1791973872218,"version":"4.4.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Exposure therapy in virtual reality (VR) is well established for anxiety disorders. While early studies show promise for VR-based exposure and response prevention (ERP) in obsessive-compulsive disorder (OCD), a key challenge of traditional VR is the weak sense of presence, deemed crucial for effectiveness.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the feasibility and efficacy of ERP in mixed reality (MERP).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This randomized clinical trial (RCT) included 2 outpatient treatment groups, MERP vs self-guided ERP (SERP) from March 15, 2022, to October 26, 2024. Participants were required to be 18 to 80 years of age and have contamination-related OCD (C-OCD). Exclusion criteria consisted of schizophrenia or bipolar disorder, severe substance use disorder, acute suicidality, and ongoing inpatient treatment. Patients\u2019 symptom severity was assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) before (baseline) and after the 6-week intervention period as well as 3 months after posttreatment (follow-up).<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Six sessions of MERP or SERP.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Main outcome was the severity of OCD symptoms in the past 7 days on the Y-BOCS. Sense of presence and subjective appraisal were the secondary outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Thirty-six participants fulfilled inclusion criteria. Twenty-four participants (66.7%) were female; mean (SD) age was 35.42 (14.03) years. Both groups had severe OCD symptoms, with major depressive disorder as the most common comorbidity (23 [63.9%]). Twenty-nine participants (80.6%) completed the postintervention and follow-up assessments. At baseline, patients in the MERP group had a mean (SD) Y-BOCS score of 26.94 (5.83), while the SERP group had a mean (SD) score of 24.22 (4.12). The decline in patients\u2019 OCD symptoms (Y-BOCS) was similar in the MERP (mean difference,\u20093.15) and the SERP groups (mean difference,\u20091.47) (\u03b7\n p<\/jats:sub>\n 2<\/jats:sup>\n \u2009=\u20090.002; 95% CI, \u20133.187 to 3.893). Significant improvements were observed within the MERP group from baseline to post treatment across several psychopathological variables, including OCD symptoms, with a medium to large effect (Cohen\n d<\/jats:italic>\n , 0.584-0.931; 95% CI, 0.026-1.551). Sense of presence was moderate (mean [SD], \u22643.24 [\u22642.07]). Subjective appraisal was heterogeneous.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This RCT on MERP in C-OCD provided important insights. While there were no significant between-group differences, changes in psychopathology within the MERP group suggest some level of effectiveness. However, the limited impact indicates that the full potential of MERP has not yet been realized, and future research should aim to improve immersion and overall effectiveness.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n German Clinical Trial Registry:\n DRKS00020969<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.11488","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:01:05Z","timestamp":1747738865000},"page":"e2511488","source":"Crossref","is-referenced-by-count":9,"title":["Exposure Therapy in Mixed Reality for Obsessive-Compulsive Disorder"],"prefix":"10.1001","volume":"8","author":[{"given":"Franziska","family":"Miegel","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Jelinek","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzie","family":"Lohse","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Moritz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Bl\u00f6mer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Juckoff","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Yassari","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Rolvien","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"4","key":"zoi250390r1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19r13085","article-title":"Women are at greater risk of OCD than men.","volume":"81","author":"Fawcett","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"zoi250390r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2021.152223","article-title":"Cognitive behavioural therapy with exposure and response prevention in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of randomised controlled trials.","volume":"106","author":"Reid","year":"2021","journal-title":"Compr Psychiatry"},{"issue":"2","key":"zoi250390r4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/16506073.2018.1494750","article-title":"\u201cPhobie \u00e0 deux\u201d and other reasons why clinicians do not apply exposure with response prevention in patients with obsessive-compulsive disorder.","volume":"48","author":"Moritz","year":"2019","journal-title":"Cogn Behav Ther"},{"issue":"7","key":"zoi250390r5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1176\/appi.ps.202000296","article-title":"Defining and addressing gaps in care for obsessive-compulsive disorder in the United States.","volume":"72","author":"Senter","year":"2021","journal-title":"Psychiatr Serv"},{"key":"zoi250390r6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.janxdis.2016.03.006","article-title":"Dropout rates in exposure with response prevention for obsessive-compulsive disorder: What do the data really say?","volume":"40","author":"Ong","year":"2016","journal-title":"J Anxiety Disord"},{"key":"zoi250390r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2020.152174","article-title":"How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician\u2019s guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology.","volume":"100","author":"Fineberg","year":"2020","journal-title":"Compr Psychiatry"},{"key":"zoi250390r8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3389\/fpsyt.2019.00773","article-title":"Using virtual reality exposure therapy to enhance treatment of anxiety disorders: identifying areas of clinical adoption and potential obstacles.","volume":"10","author":"Boeldt","year":"2019","journal-title":"Front Psychiatry"},{"key":"zoi250390r9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.janxdis.2018.08.003","article-title":"Virtual reality exposure therapy for anxiety and related disorders: a meta-analysis of randomized controlled trials.","volume":"61","author":"Carl","year":"2019","journal-title":"J Anxiety Disord"},{"issue":"3","key":"zoi250390r10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/cpp.2623","article-title":"The use of virtual reality in assessment and treatment of anxiety and related disorders.","volume":"28","author":"Meyerbr\u00f6ker","year":"2021","journal-title":"Clin Psychol Psychother"},{"issue":"5","key":"zoi250390r11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ijop.12919","article-title":"Expected increase in health competence improves over modules of an unguided internet-based cognitive-behavioural therapy for obsessive-compulsive disorder.","volume":"58","author":"Miegel","year":"2023","journal-title":"Int J Psychol"},{"key":"zoi250390r12","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-022-09992-5","article-title":"Exposure and response prevention in virtual reality for obsessive-compulsive disorder: a case series.","author":"Miegel","year":"2022","journal-title":"Psychiatr Q"},{"key":"zoi250390r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocrd.2020.100518","article-title":"The use of virtual reality (VR) exposure for reducing contamination fear and disgust: can VR be an effective alternative exposure technique to in vivo?","volume":"25","author":"Inozu","year":"2020","journal-title":"J Obsessive Compuls Relat Disord"},{"key":"zoi250390r14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.618874","article-title":"Design and validation of augmented reality stimuli for the treatment of cleaning obsessive-compulsive disorder.","volume":"12","author":"Garc\u00eda-Batista","year":"2021","journal-title":"Front Psychol"},{"key":"zoi250390r15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1272783","article-title":"Mixed reality for a collective and adaptive mental health metaverse.","volume":"14","author":"Navas-Medrano","year":"2024","journal-title":"Front Psychiatry"},{"issue":"10","key":"zoi250390r16","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jclp.23550","article-title":"Mixed results for exposure and response prevention therapy in mixed reality for patients with contamination-related obsessive-compulsive disorder: a randomized controlled pilot study.","volume":"79","author":"Miegel","year":"2023","journal-title":"J Clin Psychol"},{"issue":"20","key":"zoi250390r17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"zoi250390r18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40359-023-01116-3","article-title":"Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial.","volume":"11","author":"Lohse","year":"2023","journal-title":"BMC Psychol"},{"key":"zoi250390r19","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"zoi250390r20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability.","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"zoi250390r21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1037\/1040-3590.14.4.485","article-title":"The Obsessive-Compulsive Inventory: development and validation of a short version.","volume":"14","author":"Foa","year":"2002","journal-title":"Psychol Assess"},{"issue":"10","key":"zoi250390r23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7.","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"12","key":"zoi250390r24","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0277-9536(98)00009-4","article-title":"The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties.","volume":"46","author":"TheWHOQOL Group","year":"1998","journal-title":"Soc Sci Med"},{"issue":"4","key":"zoi250390r26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses.","volume":"41","author":"Faul","year":"2009","journal-title":"Behav Res Methods"},{"key":"zoi250390r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbtep.2023.101893","article-title":"Impact of virtual reality applications in the treatment of anxiety disorders: A systematic review and meta-analysis of randomized-controlled trials.","volume":"81","author":"Schr\u00f6der","year":"2023","journal-title":"J Behav Ther Exp Psychiatry"},{"issue":"1","key":"zoi250390r28","first-page":"37","article-title":"Virtual reality exposure for ocd: is it feasible?","volume":"19","author":"Belloch","year":"2014","journal-title":"Rev Psicopatol Psicol Clin"},{"issue":"1","key":"zoi250390r29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.beth.2018.04.004","article-title":"Predictors and moderators of cognitive and behavioral therapy outcomes for OCD: a patient-level mega-analysis of eight sites.","volume":"50","author":"Steketee","year":"2019","journal-title":"Behav Ther"},{"issue":"2","key":"zoi250390r30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jbtep.2009.10.006","article-title":"Predicting outcome of treatment for severe, treatment resistant OCD in inpatient and community settings.","volume":"41","author":"Boschen","year":"2010","journal-title":"J Behav Ther Exp Psychiatry"},{"key":"zoi250390r31","doi-asserted-by":"publisher","DOI":"10.3389\/frvir.2021.736793","article-title":"a pilot study exploring age differences in presence, workload, and cybersickness in the experience of immersive virtual reality environments.","volume":"2","author":"Dilanchian","year":"2021","journal-title":"Front Virtual Real"},{"key":"zoi250390r2","volume-title":"2019 Surveillance of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder: Treatment (NICE guideline CG31)","author":"National Institute for Health and Care Excellence (NICE)","year":"2019"},{"key":"zoi250390r22","volume-title":"Beck Depression Inventory-II","author":"Beck","year":"1996","edition":"2nd ed"},{"key":"zoi250390r25","unstructured":"Lombard? M, Ditton? TB, Weinstein? L. Measuring presence: the Temple Presence Inventory. January 14, 2009. Accessed March 14, 2024. https:\/\/api.semanticscholar.org\/CorpusID:11759204"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2834260\/miegel_2025_oi_250390_1747095365.04198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:01:07Z","timestamp":1747738867000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2834260"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.11488","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}